Latest News

Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Nov

25

2020

Senhwa Announces Multiple IND application submissions to U.S. FDA for Silmitasertib as a Potential Treatment for COVID-19

Nov

02

2020

Coronavirus Breakthrough: Senhwa Reports First eIND Silmitasertib Treated Severe COVID-19 Patient - Discharged Following Five Days of Treatment

Sep

11

2020

Senhwa Biosciences’s Silmitasertib Receives Rare Pediatric Disease Designation from U.S. FDA for Treatment of Recurrent Sonic Hedgehog Medulloblastoma

Jul

06

2020

Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19

Jul

02

2020

Senhwa’s Abstract of Silmitasertib for the Treatment of Basal Cell Carcinoma Clinical Trial Accepted for 2020 ASCO Online Publication

May

14

2020

Senhwa Biosciences Silmitasertib Named as Potential Covid-19 Therapy

Mar

31

2020

Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS

Dec

13

2019